<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36460467</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Association Between Serum Lipids and Survival in Patients With Amyotrophic Lateral Sclerosis: A Meta-analysis and Population-Based Study.</ArticleTitle><Pagination><StartPage>e1062</StartPage><EndPage>e1071</EndPage><MedlinePgn>e1062-e1071</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000201657</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE">To explore the association between lipids, polygenic profile scores (PPS) for biomarkers of lipid metabolism, markers of disease severity, and survival in patients with amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="METHODS">We meta-analyzed the current literature on the prognostic value of lipids in patients with ALS. Subsequently, we evaluated the relationship between lipid levels at diagnosis, clinical disease stage, and survival in all consecutive patients diagnosed in the Netherlands. We determined the hazard ratio (HR) of each lipid for overall survival, defined as death from any cause. A subset of patients was matched to a previous genome-wide association study; data were used to calculate PPS for biomarkers of lipid metabolism and to determine the association between observed lipid levels at diagnosis and survival.</AbstractText><AbstractText Label="RESULTS">Meta-analysis of 4 studies indicated that none of the biomarkers of the lipid metabolism were statistically significantly associated with overall survival; there was, however, considerable heterogeneity between study results. Using individual patient data (N = 1,324), we found that increased high-density lipoprotein (HDL) cholesterol was associated with poorer survival (HR of 1.33 (95% CI 1.14-1.55, <i>p</i> &lt; 0.001)). The correlation between BMI and HDL cholesterol (Pearson <i>r</i> -0.26, 95% CI -0.32 to -0.20) was negative and between BMI and triglycerides (TG) positive (Pearson <i>r</i> 0.18, 95% CI 0.12-0.24). Serum concentrations of total cholesterol and LDL cholesterol were lower in more advanced clinical stages (both <i>p</i> &lt; 0.001). PPS for biomarkers of lipid metabolism explained 1.2%-13.1% of their variance at diagnosis. None of the PPS was significantly associated with survival (all <i>p</i> &gt; 0.50).</AbstractText><AbstractText Label="DISCUSSION">Lipids may contain valuable information about disease severity and prognosis, but their main value may be driven as a consequence of disease progression. Our results underscore that gaining further insight into lipid metabolism and longitudinal data on serum concentrations of the lipid profile could improve the monitoring of patients and potentially further disentangle ALS pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janse van Mantgem</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0002-5782-1980</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (M.R.J.M., W.R., A.V.H., M.A.E., J.H.V., L.H.B., R.P.A.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (R.P.A.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rheenen</LastName><ForeName>Wouter</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-5860-1533</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (M.R.J.M., W.R., A.V.H., M.A.E., J.H.V., L.H.B., R.P.A.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (R.P.A.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hackeng</LastName><ForeName>Anemone V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.R.J.M., W.R., A.V.H., M.A.E., J.H.V., L.H.B., R.P.A.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (R.P.A.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.R.J.M., W.R., A.V.H., M.A.E., J.H.V., L.H.B., R.P.A.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (R.P.A.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-5572-9657</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (M.R.J.M., W.R., A.V.H., M.A.E., J.H.V., L.H.B., R.P.A.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (R.P.A.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.R.J.M., W.R., A.V.H., M.A.E., J.H.V., L.H.B., R.P.A.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (R.P.A.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands. lberg@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><Identifier Source="ORCID">0000-0002-7132-5967</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (M.R.J.M., W.R., A.V.H., M.A.E., J.H.V., L.H.B., R.P.A.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (R.P.A.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>21</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36460467</ArticleId><ArticleId IdType="pmc">PMC9990853</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000201657</ArticleId><ArticleId IdType="pii">WNL.0000000000201657</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tracey TJ, Kirk SE, Steyn FJ, Ngo ST. The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis. Semin Cell Dev Biol. 2021;112:69-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">32962914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha-Oliveira T, Montezinho L, Mendes C, et al. . Oxidative stress in amyotrophic lateral sclerosis: pathophysiology and opportunities for pharmacological intervention. Oxid Med Cell Longev. 2020;2020:1-29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683149</ArticleId><ArticleId IdType="pubmed">33274002</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, et al. . Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11):1108-1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot SJ, Bolborea M, Dupuis L. Dysregulation of energy homeostasis in amyotrophic lateral sclerosis. Curr Opin Neurol. 2021;34(5):773-780.</Citation><ArticleIdList><ArticleId IdType="pubmed">34343139</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RA, Bakker MK, et al. . Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53:1636-1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Talbot K, Turner MR. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2021;0:1-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8685635</ArticleId><ArticleId IdType="pubmed">34518331</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Khalik J, Yutuc E, Crick PJ, et al. . Defective cholesterol metabolism in amyotrophic lateral sclerosis. J Lipid Res. 2017;58(1):267-278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234729</ArticleId><ArticleId IdType="pubmed">27811233</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448-457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Bai Z, Qin X, Cheng Y. Aberrations in oxidative stress markers in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Oxid Med Cell Longev. 2019;2019:1-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590548</ArticleId><ArticleId IdType="pubmed">31281567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Chen L, Zhan Y, Termorshuizen J, Yin L, Fang F. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. 2020;94(17):1-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="pubmed">32221024</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, K&#xfc;hnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613-617.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Highton-Williamson E, Caga J, et al. . Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behavior and cognition. J Alzheimer&#x2019;s Dis. 2018;61(2):773-783.</Citation><ArticleIdList><ArticleId IdType="pubmed">29254092</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R, Guo X, Chen X, et al. . The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Front Degener. 2015;16(5&#x2010;6):359-365.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121273</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, et al. . Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004-1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Dorst J, Dreyhaupt J, et al. . Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2020;87(2):206-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills A-M, Hubbard J, Macklin EA, et al. . Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383(9934):2065-2072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World federation of neurology research group on motor neuron diseases. El escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1(5):293-299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden JA, van der Windt DA, Cartwright JL, Co P. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280-286.</Citation><ArticleIdList><ArticleId IdType="pubmed">23420236</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;ver C, Bender R, Dias S, et al. . On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis. Res Synth Methods. 2021;12(4):448-474.</Citation><ArticleIdList><ArticleId IdType="pubmed">33486828</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, et al. . A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(3):847-852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Network to Cure ALS (ENCALS) E. King's ALS Staging SOP. 2014; Accessed May 1, 2021.</Citation></Reference><Reference><Citation>Cooper-Knock J, Hewitt C, Highley JR, et al. . Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012;135(3):751-764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening: influence of fasting state on cholesterol results and management decisions. J Gen Intern Med. 2000;15(6):395-399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1495473</ArticleId><ArticleId IdType="pubmed">10886474</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. . Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423-433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265-267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse Van Mantgem MR, Van Eijk RPA, Van Der Burgh HK, et al. . Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020;91(8):867-875.</Citation><ArticleIdList><ArticleId IdType="pubmed">32576612</ArticleId></ArticleIdList></Reference><Reference><Citation>White I, Royston P. Imputing missing covariate values for the Coxmodel. Stat Med. 2009;28(10):1982-1998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2998703</ArticleId><ArticleId IdType="pubmed">19452569</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin D, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10(4):585-598.</Citation><ArticleIdList><ArticleId IdType="pubmed">2057657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray NR, Lin T, Austin J, et al. . From basic science to clinical application of polygenic risk scores: a primer. JAMA Psychiatry. 2021;78(1):101-109.</Citation><ArticleIdList><ArticleId IdType="pubmed">32997097</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisner A, Kundu P, Zhang YD, et al. . Combined utility of 25 disease and risk factor polygenic risk scores for stratifying risk of all-cause mortality. Am J Hum Genet. 2020;107(3):418-431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477009</ArticleId><ArticleId IdType="pubmed">32758451</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson TG, Sanderson E, Palmerid TM, et al. . Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):1-22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089422</ArticleId><ArticleId IdType="pubmed">32203549</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Kurihara M, Ogawa N, et al. . Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: roles of sex and hypermetabolism. Sci Rep. 2022;12(1):1-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814149</ArticleId><ArticleId IdType="pubmed">35115598</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Ilardi A, et al. . Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73(20):1681-1685.</Citation><ArticleIdList><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwingshackl L, Hoffmann G. Comparison of effects of long-term low-fat vs high-fat diets on blood lipid levels in overweight orObese patients: a systematic review and meta-analysis. J Acad Nutr Diet. 2013;113(12):1640-1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">24139973</ArticleId></ArticleIdList></Reference><Reference><Citation>Poobalan A, Aucott L, Smith WCS, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Obes Rev. 2004;5:43-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">14969506</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamai L, Lurix E, Shen M, et al. . Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese. Obes Surg. 2011;21(1):42-47.</Citation><ArticleIdList><ArticleId IdType="pubmed">20563664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigini P, Steffensen KR, Ferrario A, et al. . Neuropathologic and biochemical changes during disease progression in liver x receptor &#x3b2;-/-mice, a model of adult neuron disease. J Neuropathol Exp Neurol. 2010;69(6):593-605.</Citation><ArticleIdList><ArticleId IdType="pubmed">20467332</ArticleId></ArticleIdList></Reference><Reference><Citation>De Aguilar JLG. Lipid biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2019;10(APR):1-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6458258</ArticleId><ArticleId IdType="pubmed">31019485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Chen X, Han J, Jiang W, Natarajan P, Zhao H. Interactions between enhanced polygenic risk scores and lifestyle for cardiovascular disease, diabetes, and lipid levels. Circ Genomic Precis Med. 2021;14(1):1-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887077</ArticleId><ArticleId IdType="pubmed">33433237</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdom CJ, Janse van Mantgem MR, van Eijk RPA, et al. . Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2021;28(11):3615-3625.</Citation><ArticleIdList><ArticleId IdType="pubmed">34216521</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig W, Palomaki G, Haddow J. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ. 1989;298(6676):784-788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1836079</ArticleId><ArticleId IdType="pubmed">2496857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakafika A, Athyros V, Tziomalos K, Karagiannis A, Mikhailidis D. High density lipoprotein cholesterol and statin trials. Curr Med Chem. 2008;15(22):2265-2270.</Citation><ArticleIdList><ArticleId IdType="pubmed">18781948</ArticleId></ArticleIdList></Reference><Reference><Citation>Balder JW, de Vries JK, Nolte IM, Lansberg PJ, Kuivenhoven JA, Kamphuisen PW. Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: age- and gender-specific baseline lipid values and percentiles. J Clin Lipidol. 2017;11(4):1055-1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">28697983</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard BG, Langsted A, Mora S, et al. . Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points - a joint consensus statement from the European Atherosclerosis Society and European Fede. Eur Heart J. 2016;37(25):1944-1958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4929379</ArticleId><ArticleId IdType="pubmed">27122601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Lee E, Bradburn M, Mcdermott CJ, Shaw PJ. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime clinical trial. Amyotroph Lateral Scler Front Degener. 2015;16(7&#x2010;8):478-484.</Citation><ArticleIdList><ArticleId IdType="pubmed">26161993</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurmohamed NS, Collard D, Balder JW, Kuivenhoven JA, Stroes ESG, Reeskamp LF. From evidence to practice: development of web-based Dutch lipid reference values. Neth Hear. J. 2021;29(9):441-450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8397806</ArticleId><ArticleId IdType="pubmed">33844162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipid Tools. 2022. 
https://www.lipidtools.com/calculator-pages/reference/</Citation></Reference><Reference><Citation>Barone M, Viggiani MT, Introna A, et al. . Nutritional prognostic factors for survival in amyotrophic lateral sclerosis patients undergone percutaneous endoscopic gastrostomy placement. Amyotroph Lateral Scler Front Degener. 2019;20(7&#x2010;8):490-496.</Citation><ArticleIdList><ArticleId IdType="pubmed">31347407</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, van der Schouw YT, Fischer K, et al. . Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(6):638-642.</Citation><ArticleIdList><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>